Somewhat Positive News Coverage Somewhat Unlikely to Affect OraSure Technologies (OSUR) Share Price

Media coverage about OraSure Technologies (NASDAQ:OSUR) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OraSure Technologies earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 45.8356186459151 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

Shares of OraSure Technologies (OSUR) opened at $17.40 on Wednesday. OraSure Technologies has a 1 year low of $8.39 and a 1 year high of $23.01. The stock has a market cap of $1,053.46, a PE ratio of 33.40, a price-to-earnings-growth ratio of 3.34 and a beta of 1.28.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. During the same period in the prior year, the business posted $0.11 earnings per share. The company’s revenue was up 31.0% on a year-over-year basis. analysts forecast that OraSure Technologies will post 0.42 EPS for the current fiscal year.

Several research analysts recently issued reports on OSUR shares. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, November 4th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, Jefferies Group reiterated a “buy” rating and issued a $23.00 target price on shares of OraSure Technologies in a research report on Friday, October 20th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.21.

In other OraSure Technologies news, Director Mara G. Aspinall purchased 5,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Douglas A. Michels sold 25,000 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $22.55, for a total transaction of $563,750.00. Following the sale, the chief executive officer now owns 743,058 shares of the company’s stock, valued at $16,755,957.90. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect OraSure Technologies (OSUR) Share Price” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with's FREE daily email newsletter.

Leave a Reply